# Temab-A (NCT05029882)

> Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05029882
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Non-Small Cell Lung Cancer; Advanced Solid Tumors; Gastroesophageal Adenocarcinoma; Colorectal Cancer
- Interventions: ABBV-400; Trifluridine/Tipiracil; Bevacizumab
- Enrollment: 520
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on Temab-A so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 54
- Bluesky threads: 11
- YouTube: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=temab-a-nct05029882

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05029882", "email": "<work email>"}; the inbox owner confirms by the emailed link.